Current Oncology Reports

, Volume 3, Issue 2, pp 102–108

Determinants of prognosis and response to therapy in colorectal cancer

Authors

  • Syma Iqbal
    • Division of Medical OncologyUniversity of Southern California/ Norris Comprehensive Cancer Center
  • Heinz-Josef Lenz
    • Division of Medical OncologyUniversity of Southern California/ Norris Comprehensive Cancer Center
Article

DOI: 10.1007/s11912-001-0008-5

Cite this article as:
Iqbal, S. & Lenz, H. Curr Oncol Rep (2001) 3: 102. doi:10.1007/s11912-001-0008-5

Abstract

Identification of the molecular determinants of 5-fluorouracil (5-FU) and irinotecan (CPT-11) efficacy and toxicity is critically important for the development of more efficient and less toxic treatment strategies for patients with colon cancer. We have identified molecular predictors of response to chemotherapy with 5-FU and survival in patients with advanced colorectal cancer. Low gene expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and thymidine phosphorylase (TP) are associated with response and survival. Preliminary data suggest that gene expression levels of topoisomerase I, p21, bcl-2, and ICE may be predictive of response to therapy with CPT-11. Increased toxicity seen in patients treated with CPT-11 may be explained by polymorphism in the UGT1A1 gene, which is responsible for glucuronidation of the active metabolite of CPT-11.

Copyright information

© Current Science Inc. 2001